PTO/SB/21 (08-03) FW 10/786,475 **Application Number TRANSMITTAL** BTRADE Filing Date February 24, 2004 **FORM** KAREL KONVICKA First Named Inventor (to be used for all correspondence after initial filing) Art Unit Negin, Russell Scott **Examiner Name** Total Number of Pages in This Submission Attorney Docket Number 4 54801-5005-US01 (excluding references) ENCLOSURES (Check all that apply) After Allowance Communication to Group ☐ Drawing(s) Fee Transmittal Form Appeal Communication to Board of Appeals Licensing-related Papers Fee Attached and Interferences Appeal Communication to Group (Appeal Petition Amendment/Reply Notice, Brief, Reply Brief) Response to Restriction Requirement Proprietary Information After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Terminal Disclaimer Other Enclosure(s) Extension of Time Request (See (please identify below): Remarks) Return postcard Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement with Form PTO-1449; 12 References The Commissioner is authorized to charge any additional fees to Certified Copy of Priority Deposit Account 50-0310. Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Morgan, Lewis & Bockius LLP Firm

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Judi Stillwell

Signature

Date

January 19, 2007

Reg. No. 38,304

Individual Signature Robin M. Silva

OIPE 1807

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KAREL KONVICKA

Application No.: 10/786,475

Filed: February 24, 2004

For: IMPROVEMENTS TO ANALYSIS METHODS FOR INDIVIDUAL

**GENOTYPING** 

Confirmation No. 9333

Examiner: Negin, Russell Scott

Art Unit: 1631

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-SB/08B are being called to the attention of the Examiner. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee. The Commissioner is authorized to deduct the \$180.00 fee set forth in 37 C.F.R. §1.17(p) from the

01/24/2007 RMEBRAHT 00000035 500310 10786475

01 FC:1806 180.00 DA

undersigned's Deposit Account No. 50-0310 (Matter No. 054801-5005-US01). Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Date:

January 19, 2007

Robin M. Silva, Reg. No. 38,304

MORGAN LEWIS & BOCKIUS LLP 2 Palo Alto Square 3000 El Camino Real, Suite 700 Palo Alto, CA 94306-2212 (415) 442-1379

O INFORMATION DISCLOSURE				Complete If Known		
/ O'INFO	<b>MATIO</b>	ON DISCL	OSURE	Application Number	10/786,475	
	* ) - CH	ATION		Filing Date	February 24, 2004	
IAN 2 2 2007				First Named Inventor	KAREL KONVICKA	
	₽ PT	O-1449		Art Unit	1631	
Char way	7			Examiner Name	Negin, Russell Scott	
Sheet	1	of	1	Attorney Docket Number	54801-5005-US01	

			U.S. PATEN	T DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number - Kind Code <sup>1</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate	
	. A1	2002/0183933	12/05/2002	Webster et al.				
							·	
		ОТНЕ	R NON PATENT	LITERATURE DOCUMENT	ΓS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
	A2	Babu et al., "A near-optimal initial seed value selection in K-means algorithm using a genetic algorithm," Pattern Recognition Letters (1993) 14:763-769.						
	А3	Barcellos et al., "Association Mapping of Disease Loci, by Use of a Pooled DNA Genomic Screen," Am J Hum Genet (1997) 61:734-747.						
	A4	Excoffier et al., "Maximum-Likelihood Estimation of Molecular Haplotype Frequencies in a Diploid Population," <i>Mol Biol Evol</i> (1995) 12(5):921-927.						
	A5	Fan et al., "Parallel Genotyping of Human SNPs Using Generic High-density Oligonucleotide Tag Arrays," Genome Research (2000) 10:853-860.						
	A6	Frey et al., "A statistically defined endpoint titer determination method for immunoassays," J Immun Methods (1998) 221:35-41.						
	A7	Kellam et al., "Recombinant Virus Assay: a Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrob Agents Chemother</i> (1994) 38(1):23-30.						
	A8	Krishna et al., "Genetic K-Means Algorithm," <i>IEEE Transactions on Systems, Man, and Cybernetics - Part B: Cybernetics</i> (1999) 29(3):433-439.						
-	A9	Kroll et al., "Ranking: a closer look on globalisation methods for normalisation of gene expression arrays," <i>Nucleic Acids Res</i> (2002) 30(11)e50.						
	A10	Walter et al., "Prediction of Abacavir Resistance from Genotypic Data: Impact of Zidovudine and Lamivudine Resistance in Vitro and In Vivo," <i>Antimicrob Agents Chemother</i> (2002) 46(1):89-94.						
	Weisstein, "Paired t-Test," Mathworld, <a href="http://mathworld.wolfram.com/Pairedt-Test.html">http://mathworld.wolfram.com/Pairedt-Test.html</a> , printed 7/7/06.							
	A12	Xiong et al., "Comparison of the Power and Accuracy of Biallelic and Microsatellite Markers in Population-Based Gene-Mapping Methods," Am J Hum Genet (1999) 64:629-640.					ite Markers 10.	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.